Related Experiment Videos

AT1 blockers: are there alternative pathways reducing cardiovascular risk? Introduction

Peter A van Zwieten¹, Stevo Julius

¹Departments of Pharmacotherapy, Cardiology and Cardiothoracal Surgery, Academic Medical Centre, University of Amsterdam, 1105 AZ Amsterdam, The Netherlands.

Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension

|August 20, 2002

Summary

No abstract available in PubMed .

Related Concept Videos

Articles linked to this work by shared authors, journal, and citation graph.

Effects of valsartan vs amlodipine and achieved lower blood pressure on the incidence of end-stage kidney disease: The VALUE Trial.

European journal of internal medicine·2024

Cardiovascular Outcomes in Hypertension-Treated Patients With Peripheral Artery Disease: The VALUE Trial.

Hypertension (Dallas, Tex. : 1979)·2024

The current best drug treatment for hypertensive heart failure with preserved ejection fraction.

European journal of internal medicine·2023

What Is the Current Best Drug Treatment for Hypertensive Heart Failure With Preserved Ejection Fraction? Review of the Totality of Evidence.

American journal of hypertension·2023

Middle-Aged and Older Patients With Left Ventricular Hypertrophy: Higher Mortality With Drug Treated Systolic Blood Pressure Below 130 mm Hg.

Hypertension (Dallas, Tex. : 1979)·2023

Aortic Root Dilatation in Hypertensive Patients with Left Ventricular Hypertrophy-Application of A New Multivariate Predictive Model. The Life Study.

Reviews in cardiovascular medicine·2022

See all related articles